Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging

To evaluate response rates at week 16 with ixekizumab in patients with radiographic axial spondyloarthritis (r-axSpA) and elevated or normal/low baseline inflammation, measured by serum C-reactive protein (CRP) or spinal MRI, using data from 2 randomized, double-blind, placebo-controlled phase III t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Rheumatology (Oxford, England) England), 2022-11, Vol.61 (11), p.4324-4334
Hauptverfasser: Maksymowych, Walter P, Bolce, Rebecca, Gallo, Gaia, Seem, Emily, Geneus, Vladimir J, Sandoval, David M, Østergaard, Mikkel, Tada, Kurisu, Baraliakos, Xenofon, Deodhar, Atul, Gensler, Lianne S
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To evaluate response rates at week 16 with ixekizumab in patients with radiographic axial spondyloarthritis (r-axSpA) and elevated or normal/low baseline inflammation, measured by serum C-reactive protein (CRP) or spinal MRI, using data from 2 randomized, double-blind, placebo-controlled phase III trials. Biologic-naive (COAST-V) or tumor necrosis factor inhibitor-experienced (COAST-W) adults with active r-axSpA received 80 mg ixekizumab every 2 weeks (IXEQ2W) or 4 weeks (IXEQ4W) or placebo (PBO); or active reference (40 mg adalimumab Q2W; ADA) in COAST-V. At week 16, patients receiving ixekizumab continued as assigned; patients receiving PBO or ADA were re-randomized 1:1 to IXEQ2W or IXEQ4W through week 52. ASAS40 response rates were examined by baseline CRP (≤5 or > 5 mg/l) and SPARCC MRI spine inflammation score (
ISSN:1462-0324
1462-0332
DOI:10.1093/rheumatology/keac104